NCT02974504 is a Phase 4 clinical trial of evogliptin in Type2 Diabetes, sponsored by Dong-A ST Co., Ltd..

Who is sponsoring NCT02974504?

NCT02974504 is sponsored by Dong-A ST Co., Ltd..

What drugs are being tested in NCT02974504?

Interventions in NCT02974504: evogliptin, Linagliptin.

What condition does NCT02974504 study?

NCT02974504 studies Type2 Diabetes.

Is NCT02974504 still recruiting?

NCT02974504 is currently completed. Last updated 19 July 2018.

Last reviewed 2018-07-19 · How we verify

NCT02974504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double-blind, Active-contrelled, Parallel-group, Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin After Oral Administration in Patiend With Type 2 Diabetes

Completed Phase 4 Last updated 19 July 2018

What this trial tests

Phase 4 trial testing evogliptin in Type2 Diabetes in 207 participants. Completed in 1 March 2018.

Timeline

1 September 2016

Primary endpoint
1 March 2018

1 March 2018

Quick facts

Lead sponsor	Dong-A ST Co., Ltd.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	207
Start date	1 September 2016
Primary completion	1 March 2018
Estimated completion	1 March 2018
Sites	1 location across South Korea

Drugs / interventions tested

evogliptin (EVOGLIPTIN) — full drug profile →
Linagliptin (LINAGLIPTIN) — full drug profile →

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Dong-A ST Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

HbA1c
Time frame: Change from baseline at 12 week
unit: %

Sponsor's own description

A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
Kim G, Lim S, Kwon HS, Park IB, et al · · 2020 · cited 13× · PMID 32319168 · DOI 10.1111/dom.14061

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Dong-A ST Co., Ltd. trials

Trials by the same sponsor.

NCT07342062 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State · Phase 1 · completed
NCT07297940 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State · Phase 1 · completed
NCT07027982 — A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjec · Phase 1 · completed
NCT07046715 — Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 · Phase 1 · completed
NCT07007533 — A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy A · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dong-A ST Co., Ltd.
Last refreshed: 19 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing